Roche slides on side effects concerns for its weigh-loss pill
** Shares in Roche ROG.S drop around 4%, with analysts pointing to concerns around side effects of its experimental weight-loss pill, CT-996
** J.P.Morgan says in a note that the CT-996 tolerability data raises questions on overall product profile, with high rates of side effects that may not be resolved by titration
** "Overall, given the concerning tolerability profile for CT-996, which we believe may be hard to titrate away without a significant decline in efficacy," JPM says
** Titration is a process of ramping up the drug dose faster than is planned during later trial stages, in order to uncover any unforeseen side effects early
** JPM notes that CT-996 120mg dose tolerability looks uncompetitive with nausea rates of 83%, vomiting of 33% and diarrhea of 50%
** "Investor excitement for Roche's obesity franchise may now take a pause, in our view, given both acquired assets showed higher- than-anticipated GI side effects, albeit both underpinned by aggressive titration schedules," Jefferies says
** Roche's rival Novo Nordisk NOVOb.CO, the maker of Wegovy and Ozempic, is up around 3%
Reporting by Isabel Demetz
免责声明: XM Group仅提供在线交易平台的执行服务和访问权限，并允许个人查看和/或使用网站或网站所提供的内容，但无意进行任何更改或扩展，也不会更改或扩展其服务和访问权限。所有访问和使用权限，将受下列条款与条例约束：(i) 条款与条例；(ii) 风险提示；以及(iii) 完整免责声明。请注意，网站所提供的所有讯息，仅限一般资讯用途。此外，XM所有在线交易平台的内容并不构成，也不能被用于任何未经授权的金融市场交易邀约和/或邀请。金融市场交易对于您的投资资本含有重大风险。
所有在线交易平台所发布的资料，仅适用于教育/资讯类用途，不包含也不应被视为用于金融、投资税或交易相关咨询和建议，或是交易价格纪录，或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。
本网站上由XM和第三方供应商所提供的所有内容，包括意见、新闻、研究、分析、价格、其他资讯和第三方网站链接，皆保持不变，并作为一般市场评论所提供，而非投资性建议。所有在线交易平台所发布的资料，仅适用于教育/资讯类用途，不包含也不应被视为适用于金融、投资税或交易相关咨询和建议，或是交易价格纪录，或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。请确保您已阅读并完全理解，XM非独立投资研究提示和风险提示相关资讯，更多详情请点击 这里。
